Company Profiles

driven by the PitchBook Platform

Ablative Solutions

Ablative Solutions
2011 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series C LATEST DEAL TYPE
$17.9M LATEST DEAL AMOUNT
3 INVESTORS
Description

Developer of therapies and medical tools for treating hypertension designed to address the significant unmet clinical need of systemic hypertension. The company's biomedical device, Peregrine System Infusion Catheter, is a new catheter-based approach for percutaneous delivery of diagnostic and therapeutic agents into the area surrounding the peripheral blood vessels, enabling doctors to easily treat hypertension.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Primary Office
350 East Michigan Avenue
Suite 300
Kalamazoo, MI 49007
United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Ablative Solutions’s full profile, request a free trial.

Ablative Solutions Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 01-Mar-2017 $17.9M 000.00 0000 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 12-Jan-2015 000.00 000.00 000.00 Completed Startup
2. Early Stage VC (Series A) 19-Jun-2012 $5.37M $12.3M 000.00 Completed Startup
1. Early Stage VC 10-Feb-2012 $6.92M $6.92M Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Ablative Solutions Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series C 00,000,000 00.000000 00 00.0 00.00 00 00.0 00.000
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 1,649,372 $0.001000 8% $3.85 $5.78 1x $2.3 13.8%
To view this company’s complete Cap Table, request access »

Ablative Solutions Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
BioStar Ventures Venture Capital Minority 000 0000 000000 0
Grand Angels Angel Group Minority 000 0000 000000 0
Michigan Accelerator Fund 1 Venture Capital Minority 000 0000 000000 0

Ablative Solutions Executive Team (8)

Name Title Board
Seat
Contact
Info
Tim Fischell MD Co-Founder, Chief Medical Officer, Chief Executive Officer & Board Member
Vartan Ghazarossian Ph.D President, Chief Operating Officer & Board Member
Helen Parise Ph.D Vice President, Biometrics
Nicole Haratani Vice President, Global Clinical and Regulatory Affairs
Mary Adams Vice President, Global Quality Systems and Compliance

2 Former Executives

You’re viewing 5 of 8 executives. Get the full list »

Ablative Solutions Board Members (9)

Name Representing Role Since Contact
Info
Dale Grogan Michigan Accelerator Fund 1 Board Member 000 0000
David Fischell Ph.D Self Founder & Chairman 000 0000
David Rosen MD Self Board Member 000 0000
Paul Buckman Self Board Member 000 0000
Phillip Torrence JD Honigman Miller Schwartz and Cohn Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »
Questions or concerns about this profile? Reach out to website-support@pitchbook.com